生存素
荧光素酶
发起人
癌症研究
生物
分子生物学
遗传增强
报告基因
细胞培养
基因
黑色素瘤
病毒载体
基因表达
重组DNA
转染
遗传学
作者
Zeng B. Zhu,Sonia K. Makhija,Baogen Lu,Minghui Wang,Lyudmila N. Kaliberova,Bin Liu,Ángel A. Rivera,Dirk M. Nettelbeck,Parameshwar J. Mahasreshti,Charles A. Leath,Shannon D. Barker,M. Yamaoto,Fengzhi Li,Ronald D. Alvarez,David T. Curiel
标识
DOI:10.1038/sj.cgt.7700679
摘要
It has been demonstrated that survivin, a novel member of the inhibitor of apoptosis (IAP) protein family, is expressed in human cancers but is undetectable in normal differentiated tissues. We employed a recombinant adenoviral vector (reAdGL3BSurvivin) in which a tumor-specific survivin promoter and a luciferase reporter gene were inserted into the E1-deleted region of adenovirus vector. Luciferase activity was measured in both multiple tumor cell lines and two primary melanoma cells infected with reAdGL3BSurvivin. Human fibroblast and mammary epithelial cell lines were used as negative controls. A reAdGL3CMV, containing the CMV promoter and luciferase gene, was used as a positive control to normalize the luciferase activity generated by the survivin promoter. Our data revealed that the survivin promoter showed high activity in both established tumor cell lines and the primary melanoma cells. In contrast, the in vivo studies indicated that the activities of survivin promoter were extremely low in the major mouse organs. The survivin promoter appears to be a promising tumor-specific promoter exhibiting a "tumor on" and "liver off" profile, and therefore, it may prove to be a good candidate for transcriptional targeting of cancer gene therapy in a wide variety of tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI